Melbourne, April 1, 2015 - (ABN Newswire) - Rhinomed (ASX:RNO) a Melbourne based sleep and respiratory technology company is pleased to advise that it will initiate a nation wide sleep trial this Saturday night.
The nation wide trial will seek to demonstrate that Australians received an extra one-hour of sleep. The trial will be run in all states except Queensland and Western Australia. All Australians are invited to participate in the trial by registering on the Mutesnoring national sleep trial site Or at mutesnoring.com/national_sleep_trial/ “Sleep is so critical to the way we think, feel and behave. It is vital to our health and Rhinomed is committed to ensuring we help all Australians to sleep better. According to Access Economics poor sleep is costing Australia $5.1 billon annually " said CEO Michael Johnson.
The Mute technology has clearly shown that it can help people to reduce their snoring and improve their sleep. In a five-day in home user trial (n=236) in December 2014 Rhinomed demonstrated that Mute® reduced the incidence of snoring in 75% of users and radically improved sleep quality in both snorers and their partners. With over 60% of Australian households having a snorer, the company has a significant opportunity to improve the lives of millions of Australians.
This weekend the company will clearly show Australians are capable of getting an extra hour of sleep. This trial represents a great opportunity for everyone to rethink how much sleep they’re getting and the quality of sleep they need. Ensuring people breathe better at night and reduce their snoring is the first step.
All Australians are invited to trial Mute and experience the benefit of better breathing and more sleep. Mute is available for purchase at your local pharmacy or online at www.mutesnoring.com Rhinomed would also like to remind Australians that they need to put their clocks back this Saturday night as day light savings ends.
About: Rhinomed Ltd
Rhinomed Limited is a medical technology firm that focuses on nasal, respiratory and breathing management technologies. The company is monetising its technology portfolio in the Sport and recreation market, Sleep, Wellbeing and Drug delivery markets.
Rhinomed’s technology is designed to radically improve the way you breathe sleep, maintain your health and take medication.
The first product brought to market is the Turbine(TM). A radical nasal technology that improves airflow by an average of 38%, the Turbine(TM) is an internal nasal dilator that has since it’s launch in January 2014 in Australia, grown to be widely adopted by leading cyclists and triathletes globally.
Now shipped to over 36 countries and with a growing global distribution base, the Turbine(TM) is providing all those undertaking aerobic activities with an opportunity to breathe better, perform better and get more enjoyment from their sport and exercise.
Help employers find you! Check out all the jobs and post your resume.
